# Autonomic Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/autonomic-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Mountain View, US
- Website: www.ati-spg.com
- Total disclosed funding: $86M
- Latest round: Series D (Jun 25, 2015)
- Investors on record: 10

## About

Autonomic Technologies, Inc. specializes in developing innovative neuromodulation devices aimed at treating central nervous system conditions, enhancing the quality of healthcare through advanced therapeutic technologies.Autonomic Technologies, Inc. was founded in 2007 and is headquartered in Mountain View, US. The company focuses on creating neuromodulation devices for various neurological conditions. In June 2015, the company raised USD 5.5 mn in a Series D financing round from HBM Partners, which was part of a larger USD 43.2 mn Series D financing. The company has completed a total of 5 deals since its inception.Autonomic Technologies, Inc. specializes in the development of innovative neuromodulation devices aimed at treating various central nervous system (CNS) conditions. The flagship product, the Pulsante™ Implant, is a battery-free, wireless microstimulation device designed for the minimally invasive treatment of conditions such as cluster headaches and acute ischemic strokes. Activated by a handheld remote device, the Pulsante™ RC-200 emits variable radiowave frequencies that power the implant, allowing for real-time monitoring of treatment outcomes. The technology specifically targets the sphenopalatine ganglion (SPG), providing a crucial intervention for patients suffering from chronic headache disorders and other neurological ailments. The devices are currently in use within the United States and Europe, serving a growing client base that includes healthcare providers and patients seeking effective, non-invasive therapeutic options.Autonomic Technologies, Inc. operates on a transactional structure that includes direct sales to healthcare providers and potential partnerships with medical institutions for the distribution of its products. The revenue model is primarily based on sales of the Pulsante™ Implant and the RC-200 Device, utilized in clinical settings for patient treatment. Revenue is generated through initial device sales along with ongoing service agreements that may include device maintenance and software updates. The company seeks to establish long-term relationships with healthcare facilities, ensuring access to the latest advancements in neuromodulation therapy.Autonomic Technologies, Inc. plans to further its growth by designing new products aimed at addressing additional neurological conditions. The company is exploring expansion into new markets, specifically targeting regions across Europe and Asia by 2026. The recent Series D funding of USD 5.5 mn will be utilized to support these initiatives, facilitating product development and market entry strategies.

## Funding rounds

- Series D, Jun 25, 2015, $5.5M — HBM Partners
- Series D, May 11, 2015, $25M — InterWest Partners, Kleiner Perkins, Andera Partners, Aberdare Ventures, Novartis Venture Fund, Forbion, Edmond de Rothschild Asset Management, Cleveland Clinic Ventures
- Series C, Oct 12, 2011, $32M — InterWest Partners, Kleiner Perkins, Versant Ventures, Aberdare Ventures, Novartis Venture Fund
- Series B, May 22, 2009, $20M — InterWest Partners
- Series A, Dec 28, 2007, $3M — Kleiner Perkins, Cleveland Clinic Ventures

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series C, Series D
- Cleveland Clinic Ventures (https://capitalatlas.ai/funds/cleveland-clinic-ventures) — Series A, Series D
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series B, Series C, Series D
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series C
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series C, Series D
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C, Series D
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series D
- Forbion (https://capitalatlas.ai/funds/forbion) — Series D
- Edmond de Rothschild Asset Management (https://capitalatlas.ai/funds/edmond-de-rothschild-asset-management) — Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D